Zhifei Biological: Adsorbed Tetanus Vaccine Enters Phase I/III Clinical Trials

How can this clinical trial help Zhifei Biological improve its vaccine product line?

According to Every Day AI News, Zhifei Biological (300122) announced on March 26 that the adsorbed tetanus vaccine developed by its wholly-owned subsidiary Beijing Zhifei Green Bamboo Biological Pharmaceutical Co., Ltd. is conducting a Phase I/III clinical trial in Chongqing.

Every Day Economic News

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin